Authors
Vijayachitra Modhukur, Naisarg Patel, Prakash Lingasamy
Published in
Frontiers in oncology. Volume 16. Pages 1994216. Epub Oct 29, 2026.
Abstract
Explainable artificial intelligence (XAI) is increasingly used in molecular and multimodal oncology to identify features that influence machine-learning predictions. A model-important feature may subsequently be described as a biomarker, mechanistic driver or therapeutic target, although these labels represent distinct scientific claims requiring different evidence. We propose the XAI Biomarker Translation Matrix, a claim-specific conceptual framework separating explanation evidence (E), biological evidence (B) and translational evidence (T). A claim gate routes XAI-prioritised candidates into three validation pathways: diagnostic, prognostic or treatment-predictive biomarkers; mechanistic therapeutic targets; and tumour-selective delivery targets. The explanation dimension is XAI-specific and addresses whether attribution is defined, stable, faithful and reproducible, whereas the biological and translational dimensions connect the attributed feature to claim-appropriate evidence. Claim-evidence concordance requires terminology to remain no stronger than the evidence demonstrated for the intended use, and falsification-first translation asks investigators to prespecify the observation most capable of challenging the proposed interpretation. Complementing established AI-reporting, biomarker-validation and target-assessment standards, the matrix adds an XAI-specific explanation-evidence layer and an explicit claim gate linking attribution to claim-specific evidence and terminology: XAI prioritises candidates; the claim determines the validation pathway.
PMID:
43022019
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0